p53 protects against alcoholic fatty liver disease via ALDH2 inhibition.
Yao P, Zhang Z, Liu H, Jiang P, Li W, Du W.
EMBO J. 2023 Apr 17;42(8):e112304. doi: 10.15252/embj.2022112304. Epub 2023 Feb 24.
Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARalpha to activate the NF-kappaB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance.
Kong L, Chen J, Ji X, Qin Q, Yang H, Liu D, Li D, Sun M.
J Exp Clin Cancer Res. 2021 Jan 7;40(1):18. doi: 10.1186/s13046-020-01782-w.
Experimental models of metabolic and alcoholic fatty liver disease.
Buyco DG, Martin J, Jeon S, Hooks R, Lin C, Carr R.
World J Gastroenterol. 2021 Jan 7;27(1):1-18. doi: 10.3748/wjg.v27.i1.1.
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y, Fukusato T.
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide.
Nikolova-Karakashian M.
Adv Biol Regul. 2018 Dec;70:40-50. doi: 10.1016/j.jbior.2018.11.004. Epub 2018 Nov 14.
Insights of mitochondrial involvement in alcoholic fatty liver disease.
Subramaiyam N.
J Cell Physiol. 2023 Oct;238(10):2175-2190. doi: 10.1002/jcp.31100. Epub 2023 Aug 29.
Pathogenesis of alcoholic fatty liver disease: Molecular and cellular changes.
Azahar SN, Yong CK, Fahami NAM, Ibrahim IA.
Malays J Pathol. 2025 Dec;47(3):377-400.
Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis.
Lieber CS.
Alcohol. 2004 Aug;34(1):9-19. doi: 10.1016/j.alcohol.2004.07.008.
Molecular mechanisms of alcoholic fatty liver.
Purohit V, Gao B, Song BJ.
Alcohol Clin Exp Res. 2009 Feb;33(2):191-205. doi: 10.1111/j.1530-0277.2008.00827.x. Epub 2008 Nov 19.
The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies.
Rabelo ACS, Andrade AKL, Costa DC.
Nutrients. 2024 Apr 15;16(8):1174. doi: 10.3390/nu16081174.
